Subscribe to RSS
DOI: 10.1055/s-0030-1255166
© Georg Thieme Verlag KG Stuttgart · New York
Prädiktive Medizin – Klinische Genetik 2010
Predictive medicine – clinical genetics 2010Publication History
Publication Date:
16 June 2010 (online)
Was ist neu?
-
Molekulare Analysen: Mit Array-Analysen können viele Gene gleichzeitig untersucht werden.
-
Mutationen: Mutationsanalysen bedeuten vor allem bei onkologischen Erkrankungen eine Verbesserung der Therapie.
-
Polymorphismen: Genomweite Assoziations-studien ermöglichen individuelle Risikoabschätzungen für bestimmte Erkrankungen.
-
Signaturanalysen: Suche nach der Funktion, Regulation und Interaktion der Gene und der Genexpression.
Literatur
- 1 Alizadeh A A, Eisen M B, Davis R E. et al . Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403 503-511
- 2 Ashley E A, Butte A J, Wheeler M T. et al . Clinical assessment incorporating a personal genome. Lancet. 2010; 375 1525-1535
- 3 Asselah T, Bieche I, Laurendeau I. et al . Liver gene expression signature of mild fibrosis in patients with chronic hepatitis C. Gastroenterology. 2005; 129 2064-2075
- 4 Bild A H, Yao G, Chang J T. et al . Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature. 2006; 439 353-357
- 5 Blum H E. [Molecular medicine – personalized medicine. Principles and state-of-the-art]. Dtsch Med Wochenschr. 2005; 130 1568-1572
- 6 Boyault S, Rickman D S, de Reynies A. et al . Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology. 2007; 45 42-52
- 7 Caskey C T. Using genetic diagnosis to determine individual therapeutic utility. Annu Rev Med. 2010; 61 1-15
- 8 Chang J C, Wooten E C, Tsimelzon A. et al . Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet. 2003; 362 362-369
- 9 Chen H Y, Yu S L, Chen C H. et al . A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med. 2007; 356 11-20
- 10 Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med. 2008; 358 1160-1174
- 11 Cunningham D, Atkin W, Lenz H J. et al . Colorectal cancer. Lancet. 2010; 375 1030-1047
- 12 Di Nicolantonio F, Martini M, Molinari F. et al . Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008; 26 5705-5712
- 13 Dragani T A. Risk of HCC: genetic heterogeneity and complex genetics. J Hepatol. 2010; 52 252-257
- 14 Dufour J F, Johnson P. Liver cancer: from molecular pathogenesis to new therapies: summary of the EASL single topic conference. J Hepatol. 2010; 52 296-304
- 15 Dunckley T, Huentelman M J, Craig D W. et al . Whole-genome analysis of sporadic amyotrophic lateral sclerosis. N Engl J Med. 2007; 357 775-788
- 16 Fallik D, Borrini F, Boige V. et al . Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Res. 2003; 63 5738-5744
- 17 Fellay J, Thompson A J, Ge D. et al . ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature. 2010; 464 405-408
- 18 Goldstein D B. Common genetic variation and human traits. N Engl J Med. 2009; 360 1696-1698
- 19 Hafler D A, Compston A, Sawcer S. et al . Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med. 2007; 357 851-862
- 20 Herbst R S, Lippman S M. Molecular signatures of lung cancer – toward personalized therapy. N Engl J Med. 2007; 356 76-78
- 21 Hidalgo M. Pancreatic cancer. N Engl J Med. 2010; 362 1605-1617
- 22 Hood L, Heath J R, Phelps M E, Lin B. Systems biology and new technologies enable predictive and preventative medicine. Science. 2004; 306 640-643
- 23 Huang E, Cheng S H, Dressman H. et al . Gene expression predictors of breast cancer outcomes. Lancet. 2003; 361 1590-1596
- 24 Iizuka N, Oka M, Yamada-Okabe H. et al . Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet. 2003; 361 923-929
- 25 International HapMap Consortium . A haplotype map of the human genome. Nature. 2005; 437 1299-1320
- 26 Ji J, Shi J, Budhu A. et al . MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med. 2009; 361 1437-1447
- 27 Karapetis C S, Khambata-Ford S, Jonker D J. et al . K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008; 359 1757-1765
- 28 Kraft P, Hunter D J. Genetic risk prediction – are we there yet?. N Engl J Med. 2009; 360 1701-1703
- 29 Lander E S, Linton L M, Birren B. et al . Initial sequencing and analysis of the human genome. Nature. 2001; 409 860-921
- 30 Lee J S, Thorgeirsson S S. Comparative and integrative functional genomics of HCC. Oncogene. 2006; 25 3801-3809
- 31 Lenz G, Wright G, Dave S S. et al . Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008; 359 2313-2323
- 32 Liu R, Wang X, Chen G Y. et al . The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med. 2007; 356 217-226
- 33 Luo J H, Ren B, Keryanov S. et al . Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas. Hepatology. 2006; 44 1012-1024
- 34 Manolio T A, Brooks L D, Collins F S. A HapMap harvest of insights into the genetics of common disease. J Clin Invest. 2008; 118 1590-1605
- 35 Manolio T A, Collins F S. The HapMap and genome-wide association studies in diagnosis and therapy. Annu Rev Med. 2009; 60 443-456
- 36 Marcolongo M, Young B, Dal Pero F. et al . A seven-gene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C. Hepatology. 2009; 50 1038-1044
- 37 Massague J. Sorting out breast-cancer gene signatures. N Engl J Med. 2007; 356 294-297
- 38 Mayer R J. Targeted therapy for advanced colorectal cancer – more is not always better. N Engl J Med. 2009; 360 623-625
- 39 Messersmith W A, Ahnen D J. Targeting EGFR in colorectal cancer. N Engl J Med. 2008; 359 1834-1836
- 40 Mok T S, Wu Y L, Thongprasert S. et al . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361 947-957
- 41 Petersen K F, Dufour S, Hariri A. et al . Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med. 2010; 362 1082-1089
- 42 Pham M X, Teuteberg J J, Kfoury A G. et al . Gene-Expression Profiling for Rejection Surveillance after Cardiac Transplantation. N Engl J Med. 2010; 362 1890-1900
- 43 Pineau P, Volinia S, McJunkin K. et al . miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A. 2010; 107 264-269
- 44 Pritchard K I, Shepherd L E, O’Malley F P. et al . HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med. 2006; 354 2103-2111
- 45 Rauch A, Kutalik Z, Descombes P. et al . Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 2010; 138 1338-1345, 1345 e1331 – 1337
- 46 Rosenzweig A. Scanning the genome for coronary risk. N Engl J Med. 2007; 357 497-499
- 47 Samani N J, Erdmann J, Hall A S. et al . Genomewide association analysis of coronary artery disease. N Engl J Med. 2007; 357 443-453
- 48 Samani N J, Tomaszewski M, Schunkert H. The personal genome – the future of personalised medicine?. Lancet. 2010; 375 1497-1498
- 49 Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med. 2009; 360 790-800
- 50 Stefansson H, Rye D B, Hicks A. et al . A genetic risk factor for periodic limb movements in sleep. N Engl J Med. 2007; 357 639-647
- 51 Steidl C, Lee T, Shah S P. et al . Tumor-associated macrophages and survival in classic Hodgkin’s lymphoma. N Engl J Med. 2010; 362 875-885
- 52 Suppiah V, Moldovan M, Ahlenstiel G. et al . IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009; 41 1100-1104
- 53 Tanabe K K, Lemoine A, Finkelstein D M. et al . Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. JAMA. 2008; 299 53-60
- 54 Tanaka Y, Nishida N, Sugiyama M. et al . Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009; 41 1105-1109
- 55 The International HapMap Project. Nature. 2003; 426 789-796
- 56 Thomas D L, Thio C L, Martin M P. et al . Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009; 461 798-801
- 57 Thorgeirsson S S, Lee J S, Grisham J W. Molecular prognostication of liver cancer: end of the beginning. J Hepatol. 2006; 44 798-805
- 58 Tol J, Koopman M, Cats A. et al . Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med. 2009; 360 563-572
- 59 Van Cutsem E, Kohne C H, Hitre E. et al . Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009; 360 1408-1417
- 60 Van Cutsem E. et al . Abstr. LBA4509. J Clin Oncol. 2009; 27 18s
- 61 van de Vijver M J, He Y D, van’t Veer L J. et al . A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002; 347 1999-2009
- 62 Venter J C, Adams M D, Myers E W. et al . The sequence of the human genome. Science. 2001; 291 1304-1351
- 63 Villanueva A, Minguez B, Forner A, Reig M, Llovet J M. Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med. 2010; 61 317-328
- 64 Wacholder S, Hartge P, Prentice R. et al . Performance of common genetic variants in breast-cancer risk models. N Engl J Med. 2010; 362 986-993
- 65 Wen H, Yoo S S, Kang J. et al . A new NMR-based metabolomics approach for the diagnosis of biliary tract cancer. J Hepatol. 2010; 52 228-233
- 66 Xiong Y, Fang J H, Yun J P. et al . Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology. 2010; 51 836-845
- 67 Yanagisawa K, Shyr Y, Xu B J. et al . Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet. 2003; 362 433-439
- 68 Yao J, Liang L, Huang S. et al . MicroRNA-30d promotes tumor invasion and metastasis by targeting Galphai2 in hepatocellular carcinoma. Hepatology. 2010; 51 846-856
Prof. Dr. med. Dr. h. c. mult. H. E. Blum
Abteilung Innere
Medizin II, Medizinische Universitätsklinik
Hugstetter
Straße 55
79106 Freiburg
Phone: 0761/270
3404
Fax: 0761/270 3610
Email: hubert.blum@uniklinik-freiburg.de